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NMR and MS urinary metabolic phenotyping in
kidney diseases is fit-for-purpose in the presence
of a protease inhibitor†
Claire L. Boulange´, ‡a Ilse M. Rood, b Joram M. Posma,c John C. Lindon, ac
Elaine Holmes,ac Jack F. M. Wetzels,b Jeroen K. J. Deegensb and
Manuja R. Kaluarachchi *a
Nephrotic syndrome with idiopathic membranous nephropathy as a major contributor, is characterized
by proteinuria, hypoalbuminemia and oedema. Diagnosis is based on renal biopsy and the condition is
treated using immunosuppressive drugs; however nephrotic syndrome treatment efficacy varies among
patients. Multi-omic urine analyses can discover new markers of nephrotic syndrome that can be used
to develop personalized treatments. For proteomics, a protease inhibitor (PI) is sometimes added at
sample collection to conserve proteins but its impact on urine metabolic phenotyping needs to be
evaluated. Urine from controls (n = 4) and idiopathic membranous nephropathy (iMN) patients (n = 6)
were collected with and without PI addition and analysed using 1H NMR spectroscopy and UPLC-MS.
PI-related data features were observed in the 1H NMR spectra but their removal followed by a median
fold change normalisation, eliminated the PI contribution. PI-related metabolites in UPLC-MS data had
limited effect on metabolic patterns specific to iMN. When using an appropriate data processing
pipeline, PI-containing urine samples are appropriate for 1H NMR and MS metabolic profiling of patients
with nephrotic syndrome.
Introduction
Proteinuria is an important manifestation of nephrotic syndrome
(NS). In adults the most common causes of NS include (idiopathic)
membranous nephropathy (iMN), (idiopathic) focal segmental
glomerulosclerosis (iFSGS) and minimal change disease (MCD).1
Diagnosis is based on renal biopsy and treatment consists of
prolonged aggressive therapy with (various) immunosuppressive
drugs to induce remission and to reduce the risk of renal function
deterioration.2 Not all patients respond to this therapy, and
exposure to the therapeutics puts these patients at risk of compli-
cations. Therefore there is an urgent need for prognostic and/or
diagnostic biomarkers that allow development of an individualized
treatment strategy.
Omic approaches (genomics, transcriptomics, proteomics
and metabonomics) can be used to detect biomarkers and
can help elucidate the pathological mechanisms related to
disease. Recently we have used proteomic analyses to identify
biomarkers in urinary microvesicles from patients with iMN,
iFSGS and MCN. Lysosome membrane protein 2, (Limp 2) was
identified as an upregulated biomarker in patients with iMN.3
However, the underlying pathophysiological mechanisms
linked to an increase in the glomerular Limp 2 expression
and the development of iMN remain to be understood. Ideally,
combining different omic approaches will provide the community
with a more complete profile of potential biomarkers of iMN.
In metabolic phenotyping, metabolite classes such as amino
acids, organic acids and bases, fatty acids, bile acids, lipids and
carbohydrates are routinely characterised. Changes in the level
of these metabolites represents the ultimate and measurable
response of biological systems to genetic differences, disease or
environmental stimuli.4,5 By monitoring metabolite concentra-
tions it is possible to obtain information for disease diagnosis,
explain drug activity, and enable prognosis of outcomes provid-
ing an insight into the complex biochemical processes and their
impact in human health and disease.6 To date, high resolution
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1H NMR spectroscopy and ultra-performance liquid chromato-
graphy (UPLC) or gas chromatography (GC) coupled with mass
spectrometry (MS) are the two main analytical platforms used to
generate metabolic phenotyping data.7,8 The metabolic pheno-
type of urine from chronic kidney diseases (CKD) has been well
characterised using MS and 1H NMR techniques and shows the
value of applying such an approach for investigating CKD.9,10
A wide range of biomarkers has been reported in the context
of CKD including proteins, peptides, amino acids, biogenic
amines, dicarboxylic acids, lipids, nucleotides derivatives and
phenolic compounds.11–13 Velenosi et al. showed an increase in
gut-derived uremic toxins (4-cresol sulfate, hippurate, phenyl sulfate,
pyrocatechol sulfate, 4-ethylphenyl sulfate, 4-cresyl glucuronide and
equol-7-glucuronide) in plasma and tissues of CKD rats probably
due to the dysfunction of the organic anion transporters (OAT)
1 and 3 in the kidney, which allow the renal clearance of uremic
toxins.9,10 However, only limited results are available from
metabolic phenotyping investigations of proteinuric samples
from glomerular diseases.
In epidemiological projects studying kidney diseases, there
is considerable interest in the use of urine for proteomic
analysis as these samples potentially contain proteins secreted
or shed directly from the kidney, bladder or prostate.14 For
proteomics, it was initially recommended to add a protease
inhibitor (PI) prior to freezing to prevent protein degradation
caused by endogenous proteolytic enzymes. Consequently,
some samples stored in biobanks contain PI. More recent
studies have demonstrated that a PI can interfere with proteomic
analysis. For instance, some of the PIs can form covalent bonds
with proteins, modifying their isoelectric properties. The use
of a PI in general and the specific type of PI to be employed is
still a subject of debate in the renal and urinary proteomics
community.15–17 With the increased importance of combining
multi-omics techniques, it is important to know whether these
archived samples containing a PI, are fit-for-purpose in meta-
bolic phenotyping. In this study we have investigated the effect
of PI addition on the 1H NMR and MS HILIC (ESI +/) and RP
(ESI +/) metabolic profiles of urine from normal controls (NC)
and from patients with NS due to iMN. It should be made clear
that the aim of the study was not to identify metabolic
biomarkers of the renal disease but to investigate whether
addition of a PI affected the utility of a metabolic phenotyping
analysis. Therefore, the current manuscript is concerned only
with whether the use of a PI obscures information recovery
and not with investigating the underlying biochemistry of the
disease progress. That will be the subject of a subsequent
publication. The analysis of this small sample set (NC; n = 4
and iMN; n = 6) indicated the sample class-independent
impact of the PI presence on 1H NMR and MS metabolic
profiles. Moreover, it has been shown that, after adequate
processing of the 1H NMR and MS HILIC (ESI +/) and RP
(ESI +/) urine metabolic profiles to eliminate the contribu-
tion of the PI, the data can be used to investigate the meta-
bolic differences between NC and iMN.
Results
Sample details
The characteristics of patients with iMN are summarized in Table 1.
Average urinary protein concentration was 13.2 (range 7.8–28.7)
g/24 h. All patients with iMN received supportive therapy. None of
the NC group used medication. Urine samples from NC (n = 4) and
patients with iMN (n = 6) were divided into two aliquots with
protease inhibitor added to one.
The protease inhibitor introduces contaminant peaks in the
1H NMR spectra
PI addition introduced exogenous signals superimposed onto
the endogenous metabolite peaks in the 1H NMR metabolic
profiles (Fig. S1A and B, ESI†). In particular, peaks from one
excipient, identified as mannitol, obscures peaks from several
endogenous species between 3.6 and 3.9 ppm (Fig. S1 and S2,
ESI†). Two multiplets were also identified at 7.46 and 7.8 ppm
which belong to an intermediate product of another PI con-
stituent, i.e. 4-(2-aminonoethyl) benzenesulfonyl fluoride
hydrochloride (AEBSF) or a derivative of it. The NMR variables
related to PI contaminants (at 2.05, 2.56, 3.11, 3.37, 3.67–3.89,
7.68, 7.80 ppm) were then excluded from the dataset prior to
multivariate statistical analysis to prevent sample classification
related to the PI presence.
Table 1 Characteristics of patients with idiopathic membranous nephropathy who provided samples used in this metabonomic study
Clinical characteristics Spot urine
Patient
ID
Age
(years)
Sex
(M/F)
Anti-PLA2R
titera
Serum
creatinine
(mmol l1)
Serum
albumin
(g dl1)
Proteinuria
(g/24 h) Current medication
Creatinine
(mmol l1)
Proteinuria
(g l1)
1 74 M  236 0.9 28.7 Gliclazide, enalapril, amlodipine,
simvastatin, thyrax, furosemide, nifidipine
6.5 12.9
2 72 M + 67 2.4 7.8 Furosemide, losartan 5.9 3.6
3 48 F  58 1.2 14.1 Furosemide, lisinopril, warfarin, simvastatin 1.4 2.2
4 52 M +/ 122 2.1 10.6 Enalapril, furosemide, simvastatin, clopidogrel 6.9 5.4
5 35 M + 94 1.7 7.9 Perindopril, candesartan, furosemide, dalteparin 5.0 1.4
6 28 M + 118 2.2 9.9 Candesartan, spironolactone, calcium
carbonate/cholecalciferol, insulin
aspart (a short acting form of insulin)
20.5 8.6
a Serum anti-phospholipase 2 receptor (PLA2R), an antigen that has recently been associated as a cause for iMN.43
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Presence of the PI does not affect the 1H NMR urine metabolic
comparisons of controls and iMN patients
Following the removal of the PI contaminant peaks and appli-
cation of median fold change (MFC) normalisation, principal
component analysis (PCA) of the 1H NMR spectroscopic data
revealed a good separation of the NC and iMN groups in the PC
scores plot (Fig. 1A). An alternative normalisation method, total
area normalisation, was explored and is presented in the ESI†
(Fig. S4). There was no marked difference between sample
aliquots with or without PI, indicating that the major source
of variance in the data were not related to PI addition (Fig. 1A).
The comparison of 1H NMR spectra of NC (blue and green)
and iMN (black and red) groups highlighted an increase in
the line width and reduced intensity of several spectral peaks
(Fig. S5, ESI†) and particularly hippurate in iMN individuals
compared to NC individuals (Fig. 1B). On the other hand, the
line width of the spectra from the same samples in the presence
or absence of PI were similar. The peak broadening phenom-
enon is characteristic of nonspecific binding of these small
molecules with proteins, which depending on the relative mole
fractions of the free and the bound forms, and the exchange
rate between free and bound forms, results in a shortening of
the NMR transverse relaxation time and an increase in peak
width. This is in accordance with the fact that urinary protein
concentration is significantly higher in iMN compared to NC
individuals. The peaks were not found to be lower in intensity
in the NC + PI/iMN + PI groups in comparison with the NC/
iMN, groups which also suggests that urinary protein concen-
tration, is unchanged with PI addition. Measurement of urinary
proteins by a protein assay also showed no significant difference
in samples with presence or absence of PI (Wilcoxon Mann
Whitney (WMW) p-values 4 0.05 when comparing NC versus
NC + PI or iMN versus iMN + PI) and as expected proteinuria
was higher in iMN patients compared to NC individuals
(Fig. S6, ESI†). The difference in intensity of small molecule
peaks between NC and iMN individuals could be caused by the
increased interactions of highly bound molecules with proteins
in iMN samples rather than being a reflection of direct bio-
logical changes, thus raising the false positive rate for biomarker
discovery in proteinuric kidney diseases.
To fully remove the contribution of proteins in the endo-
genous metabolic profiles, the urine samples then underwent
protein precipitation with methanol prior to NMR analysis. The
protein quantification revealed that most proteins were
removed from the urine of NC and iMN patients after protein
precipitation (Fig. S6, ESI†). After removal of PI contaminant
peaks and MFC-normalisation, the PCA scores plot showed no
clear discrimination in the urine samples between presence
and absence of PI (Fig. 1C). In addition, comparable line widths
were found for hippurate in NC, NC + PI, iMN and iMN + PI
samples indicating that a large proportion of this molecule is
Fig. 1 1H NMR spectroscopic metabolic profiles of control (NC) and nephrotic syndrome (iMN) patients with or without addition of a PI, before and after
protein precipitation. PCA score plots of iMN, iMN + PI, NC and NC + PI of 1H NMR original (without protein precipitation) data showing a discrimination
with NC/NC + PI and iMN/iMN + PI groups (A). Hippurate peak shapes in iMN (green), iMN + PI (red), NC (black) and NC + PI (blue) at 7.66 ppm
highlighting a peak broadening in 1H NMR spectra of iMN/iMN + PI groups (B). PCA score plots of protein-precipitated data presenting clustering of NC,
NC + PI, iMN and iMN + PI (C). Hippurate peaks shape at 7.66 ppm of protein precipitated data showing an increase in peak resolution in 1H NMR spectra
of iMN/iMN + PI after protein precipitation (D). Additional 1H NMR spectral sections are presented in Fig. S5 (ESI†).
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now free in solution (Fig. 1D). Importantly, the discrimination
between NC and iMN samples in PCA score plots disappeared
after protein precipitation suggesting that the largest source
of variation between NC and iMN spectra are related to the
protein content. In addition, a larger intra-group variability was
observed in the PCA first component (T1, 15% of variance) that
could also affect the discrimination between NC and iMN
groups. This may have been introduced by the variability of
the protein precipitation steps.
Orthogonal partial least squares discriminant analysis
(OPLS-DA) was employed to investigate the effect of PI in urine
metabolic profiles in the context of biomarker discovery for
iMN in the original (without protein precipitation), and the
protein–precipitated datasets. In both datasets, as expected, no
difference was found between NC and NC + PI groups, nor
between the iMN and iMN + PI groups in the OPLS-DA models
(CV-ANOVA p-values 4 0.05, Table S2, ESI†). A good discrimi-
nation was observed between NC and iMN in the original but
not in the protein-precipitated datasets (CV-ANOVA p-value =
6  104, 0.17 respectively, Table S2, ESI†). These observations
are in accordance with the PCA model. The OPLS loadings plot
allowed the establishment of the spectral regions that influ-
enced the discrimination between NC and iMN in the OPLS-DA
models (Fig. 2A and B). The correlation patterns in most of the
NMR variables of the protein-precipitated dataset were similar
to those found in the original dataset (Fig. 2B) although the
correlation coefficients were weaker. In addition, we also
observe a moderate correlation of the trigonelline level (R2 =
0.65 at 4.46 ppm) with iMN only in the protein-precipitated
dataset. Therefore, in the current study, the presence of pro-
teins in the iMN patients has limited impact on the direction of
association of biomarkers with iMN but can lower the resolu-
tion of specific peaks such as trigonelline, thus affecting the
statistical comparison. Univariate analysis of the original NMR
dataset confirmed the multivariate analysis results, i.e. that
hippurate (7.83, 7.66 ppm, 7.56 ppm), creatinine (3.06, 4.08 ppm),
phenylacetate (3.57 ppm), citrate (2.66 ppm) and unknown meta-
bolites (at 1.23 (d) and 8.35 (d) ppm) significantly decreased in iMN
patients. (WMW p-values and Benjamini–Hochberg adjusted
p-values (pFDR) o 0.05). Given the low number of samples in
both iMN and NC groups, we recognise that this study does
not have enough statistical power to identify reliable markers
of iMN, and indeed this is not the aim of the current investiga-
tion. These metabolites can only be considered as putative,
unvalidated markers of iMN. None of the iMN-associated meta-
bolites were significantly affected by PI addition (WMW p-values
and pFDR 40.05, Table 2).
The protease inhibitor introduces contaminant peaks in the
UPLC-MS metabolic profile of urine
Two types of UPLC-MS analyses were carried out. These
comprised reverse phase (RP) and hydrophilic interaction
Fig. 2 OPLS-DA loadings plots of 1H NMR original (without protein precipitation) (A) and protein precipitated (B) metabolic profiles comparing NC and
iMN. The pseudo-spectra represent the covariance between the NMR variables and the group discrimination. The positive peaks are more concentrated
in the iMN group and the negative peaks are excreted in higher concentration in the NC group. NC: normal controls, iMN: idiopathic membranous
nephropathy PI: protease inhibitor. The squared regression coefficients (R2) between the NMR variables and the logistic variable defining the groups are
mapped and color-coded onto the pseudo-spectrum. The hot colours are allocated to highly correlated variables whereas the cold colours show
variables with non-significant correlation 1: unknown, 2: citrate, 3: dimethylamine, 4: creatinine, 5: unknown, 6: glucose, 7: phenylacetate, 8: hippurate,
9: trigonelline.
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liquid chromatography (HILIC) with mass spectrometric detec-
tion using both positive and negative electrospray ionisation
modes (ES + and ES ). Mass spectrometric features relating to
the components of the PI were observed in the UPLC-MS meta-
bolic data (Fig. S3, ESI†). By HILIC UPLC-MS (ESI +), it was
possible to detect the ion from AEBSF at 204.05m/z at a retention
time of 3.54 min (Fig. S3A, ESI†). Another component, leupeptin
hemisulfate was detected in both ionisation modes using HILIC
UPLC-MS, detecting the positive ion 427.303 m/z at 4.64 min
(Fig. S3B, ESI†) and negative ion 425.285 at 4.419 min (MS data not
shown). In the RPUPLC-MS (ESI +) data, the AEBSF ion at 204.05m/z
was detected at a retention time of 3.90 min (MS data not shown).
Moreover, the component mannitol that was observed strongly in
the NMR spectra could also be detected in the HILIC-MS (ESI )
data at 181.073 m/z and retention time 4.793 min.
Such exogenous peaks cause fewer problems for MS-based
multivariate analysis than NMR features. This is because each
of the undesired non-endogenous feature comprises only a
single narrow entry in the data whereas for NMR spectroscopy
any given substance (e.g. mannitol) can show several bands
many of which can be complex multiplets of peaks.
Several UPLC-MS detectable biomarkers discriminate NC from
iMN
HILIC UPLC-MS analyses (in positive and negative ionisation
detection modes) was used to capture the signals of a large
range of metabolites from small polar molecules. The PCA
score plots (PC1 versus PC2) of the metabolic data indicated
that differences between NC and iMN groups were the main
source of variation in the HILIC UPLC-MS (ESI +) and HILIC
UPLC-MS (ESI ) data.
The pair-wise OPLS-DA models comparing NC vs. iMN were
predictive for both HILIC UPLC-MS data sets (Table S2, ESI†).
Univariate analysis was employed to investigate the data sets
for features significantly (WMW p-value o 0.05) associated to
iMN. Four metabolites (hydroxyhexanoycarnitine, asymmetric
dimethylarginine, carnitine and one unidentified substance
designated UA3) were discovered from the HILIC UPLC-MS
(ESI +) and two metabolites (a-N-phenylacetyl-glutamine and
4-cresol sulfate) were found in the HILIC UPLC-MS (ESI ) data
set (Table 2). The features and thus the metabolites they
correspond to were not significant after adjusting the WMW
p-values for the false discovery rate (pFDR 4 0.05).
RP UPLC-MS (ESI +/) analyses were also employed to
capture the signals of a large range of metabolites from less
polar molecules including lipids. The PCA score plots (PC1
versus PC2) of the metabolic data indicates that the main source
of variation (PC1) in the RP UPLC-MS (ESI +) data is between
samples with and without PI (Fig. 3), with the separation of the
data based on NC and iMN groups explained by PC2. To remove
the separation of the data based on presence or absence of
PI, the features contributing to this natural separation
Table 2 Candidate markers discriminating NC and iMN patients identified by 1H NMR spectroscopy, HILIC UPLC-MS (ESI +/), RP UPLC-MS (ESI +/)
methods using univariate data analysis. For each metabolite, the WMW p-value, pFDR and the fold change from the comparison NC vs. iMN are reported.
The association of the given metabolite to the presence of the PI is also shown. The WMW p-value, pFDR and the fold change from the comparison
NC/iMN vs. NC + PI/iMN + PI are reported
1H NMR analysis NC vs. iMN Effect of PI (NC/iMN  vs. NC + PI/iMN + PI)
Methods Metabolites 1H ppm Multiplicity MWM p-value FDR Fold changea MWM p-value FDR Fold changeb
1D standard
experiment
UA1 1.23 d 0.0095 0.0304 0.72 0.3447 1 0.84
Citrate 2.668 d 0.0190 0.0304 0.43 0.9097 1 0.95
Dimethylamine 2.722 s 0.0095 0.0304 0.36 0.6776 1 0.80
Creatinine 3.063 s 0.0095 0.0304 0.38 0.6232 1 0.88
Phenylacetate 3.57 s 0.0095 0.0304 0.67 0.5708 1 1.04
Hippurate 7.563 m 0.0095 0.0304 0.14 0.6776 1 0.90
UA2 8.35 d 0.0095 0.0304 0.17 0.85 0.99 0.78
UPLC-MS analysis NC vs. iMN
Effect of PI (NC/iMN  vs.
NC + PI/iMN + PI)
Methods Metabolites
[Adduct]
(as detected) m/z
Retention
time
(minutes)
MWM
p-value FDR
Fold
change
MWM
p-value FDR
Fold
change
HILIC UPLC
MS (ESI +)
Hydroxyhexanoycarnitine [M + H]+ 276.162 7.81 0.0095 1 0.64 1.0000 1 0.67
Asymmetric dimethylarginine [M + 2Na  H]+ 247.166 8.01 0.0190 1 1.37 0.0257 0.98 0.90
L-Carnitine [M + H]+ 162.581 7.20 0.0381 1 0.73 0.6776 0.99 0.90
UA 3 [M + H]+ 286.13 6.81 0.0381 1 0.99 0.7054 0.99 0.86
HILIC UPLC
MS (ESI )
a-N-Phenylacetyl-L-glutamine [M  H] 145.096 5.14 0.0190 1 1.89 0.0312 0.83 1.74
4-Cresol sulfate [M  H] 186.978 0.68 0.0381 1 1.01 0.0036 0.83 1.10
RP UPLC MS (ESI +) UA 4 Isotope 537.166 10.13 0.0381 1 1.49 0.5205 0.92 0.74
RP UPLC MS (ESI ) 3,4-Dihydroxyphenylalanine [M  H] 195.05 0.49 0.0095 0.26 1.86 0.6776 1 1.12
Isocitrate [M  H] 191.055 0.54 0.0095 0.26 2.83 0.1041 1 0.65
a Metabolite higher in iMN if fold change41, and lower in iMN if fold changeo1. b Metabolite higher in presence of PI if fold change41 and
lower with presence of PI if fold change o1.
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(the features associated to the presence of the PI) were excluded.
PCA of this new dataset (referred to from here on in as RP-UPLC
MS (ESI + exc)) revealed that the separation in the data based on
the presence of PI had been removed. The RP-UPLC-MS (ESI )
data displayed a natural separation based on NC and iMN
groups (Fig. 3).
The pair-wise OPLS-DA models comparing NC vs. iMN were
not significant (CV-ANOVA p-values4 0.05) in the RP UPLC-MS
(ESI +/+ exc/) data. When the data from all samples were used,
the OPLS-DAmodel comparing iMN/iMN + PI and NC/NC + PI was
predictive (CV-ANOVA = 7.2  103, 1.66  104, 2.91  106) in
RP UPLC-MS (ESI +, ESI + exc and ESI  respectively, Table S2,
ESI†). This could be a result of increased statistical power when
using the larger number of samples. It is possible, given the low
number of samples, that subtle metabolic differences between NC
and iMN aremissed usingmultivariate analysis.18 As with theHILIC
UPLC-MS data, univariate analysis was used to further investigate
the features associated to iMN. Features significantly (WMW
p-value o 0.05) associated to iMN, revealed one metabolite (an
unidentified substance designated UA4) was discovered from the RP
UPLC-MS (ESI +) and two metabolites (3,4-dihydroxyphenylalanine
and isocitrate) in the RP UPLC-MS (ESI ) sets (Table 2). These
metabolites were not significant after adjusting the WMW p-values
for the false discovery rate (pFDR4 0.05).
For each metabolite discovered in the UPLC-MS datasets
discriminating NC and iMN, the WMW p-value describing the
association of the given metabolite to the presence of PI is also
reported in Table 2. Asymmetric dimethylarginine was signifi-
cantly lower in the presence of PI (WMW p-value = 0.026) while
a-N-phenylacetyl-glutamine and 4-cresol sulphate significantly
increased with PI (WMW p-value = 0.031 and 0.004 respectively,
Table 2). These findings were based on the WMW p-value o
0.05, but did not survive after adjusting the WMW p-values for
false discovery rate (pFDR 4 0.05). The rest of the metabolites
that correlate to iMN were not significantly affected by the
presence of PI (WMW p-value o 0.05). These metabolites
include 3,4-dihydroxyphenylalanine, hydroxyhexanoylcarnitine,
isocitrate and carnitine.
Discussion
PI is often added to urine samples intended for proteomic
analysis to inhibit protease activity and thus maintain the
urinary protein pool.15 With the additional information offered
by way of metabolic phenotyping, it is important to know whether
these samples are fit for purpose. This study has explored the
influence of PI on the metabolic profile of urine and shows that
Fig. 3 Effect of PI addition on MS metabolic profiles of NC and iMN individuals. PCA score plots of NC, NC + PI, iMN and iMN + PI, in HILIC UPLC-MS
(ESI +) (A), HILIC UPLC-MS (ESI ) (B), RP UPLC-MS (ESI +) (C) and RP UPLC-MS (ESI ) (D), colored by group. NC: normal controls, iMN: idiopathic
membranous nephropathy, PI: protease inhibitor.
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use of a PI introduces contaminant peaks which can be detected
by 1H NMR spectroscopy and HILIC and RP UPLC-MS. By careful
processing of the data, taking the spectral contaminants into
account, it was possible to apply metabolic phenotyping to urine
samples with added PI.
In the 1H NMR spectra, PI contaminant peaks were found to
cover those from endogenous metabolites triggering some
difficulties in recovering the spectral information in these
regions. However, the identification of endogenous metabolites
is still possible because in general, molecules produce several
peaks across the 1H NMR chemical shift range which are not all
covered by the contaminant peaks. In addition, spectroscopic
and mathematical techniques can be employed to help recover
the obscured spectral data such as JRES spectroscopy or
STORM (subset optimization by reference matching) and
STOCSY-editing.19–22 The 1H NMR data processing is also
essential for optimising the spectral information for metabolic
phenotyping. Importantly, 1H NMR spectral alignment may
improve the selection and the removal of the PI contaminants
peaks although spectral artefacts are often introduced during
this process.23,24 In this study, MFC and total area normalisation
methods were compared (Supplementary information results,
Fig. S4, ESI†), MFC proved to be more suitable to correct for
dilution effects and this is in accordance with the literature.25
Application of the MFC normalisation is recommended where
drug metabolites or excipients are present in high concentra-
tions in urine samples.26,27 Once the contaminant peaks have
been carefully excluded and the 1H NMR spectra appropriately
processed, the data can be used for the metabolic comparison of
control individuals and iMN patients although the sample
numbers per class were low. Alternatively, protein precipitation
of urine samples eliminates the contribution of proteins in
endogenous profiles but may introduce extra intra-group variability
and obscure the true biochemical difference between iMN and
NC individuals. Several metabolites were identified as possible
biomarkers of iMN, but since the sample numbers were so low
in this study little significance can be attached to them and
a properly statistically-powered study needs to be undertaken.
PI-derived contaminants were also observed in HILIC UPLC-MS
(ESI +/) and RP UPLC-MS (ESI +/) methods; nevertheless,
non-supervised and supervised multivariate analyses high-
lighted no metabolic pattern specific to the PI presence
in all datasets except in the RP UPLC-MS (ESI +) data. In RP
UPLC-MS (ESI +) data, most of the features responsible for
sample clustering were assigned to PI related compounds
(AEBSF, leupeptin hemisulfate, trypsin inhibitor).
By comparing the features associated with iMN and those
associated with PI presence, it was found that among the
iMN-associated metabolites, two metabolites significantly
increase with PI presence while one metabolite is reduced in
the presence of the PI. This indicates that the PI probably
suppresses or enhances the ionisation of several molecules.
This comparison allows to flag potential false positive or
negative markers that could be affected by the presence of PI
and thus may be useful to identify robust and reliable biomarkers
in metabolic profiling regardless of the presence of PI. To perform
this analysis, analysis of some reference samples representative
of each sample group with the presence or absence of PI was
necessary. A large range of PI or other preservatives is commer-
cially available with different protease inhibitors and additives
whose function is generally to improve molecular stability15,28
(details of the PI product in Table S1, ESI†). Their utilisation
might result in the introduction of other contaminant peaks
and have different effects on the endogenous molecules.29
Therefore, if samples preserved in this manner are included
in metabolic phenotyping studies, a similar approach to that
described here should be carried out to evaluate the impact of
any preservative on the 1H NMR and MS metabolic profiles.
A previous study has reported degradation of protein in
samples stored with PI for three years.30 In the present study, it
was found that although PI is added to stop protease activity,
the protein pool is kept intact in the urine samples with PI. This
may be due to the relative short storage (one year) of the
samples in the presence of the PI. The utilisation of protease
inhibitors or other preservatives in different biological matrices
that contain a large amount of proteins, may modify the protein
content and thus affect the 1H NMR spectroscopic and MS
metabolic profiles.31–33 It is well known that proteins in bio-
fluids can introduce large broad peaks in 1H NMR spectra that
obscure peaks from small molecule metabolites and additionally
they can lower the detectability of small molecules through
protein binding.33,34 Therefore it is also advisable to estimate
whether preservative addition increases the protein concen-
tration in the samples.
Of note, drugs, preservatives and other biological additives
often do not list the excipients and non-essential ingredients in
the product composition. In this case, the mannitol which may
be used as a binder/filler in the formulation of the PI tablet,35
was identified in high concentration in 1H NMR spectral urine
profiles of NC + PI and iMN + PI patients although they are not
mentioned in the Roche PI tablet description (Table S1, ESI†).
The main limitation of this study is the low sample size,
which is a drawback when identifying metabolic difference
between NC and iMN. The relatively low number of discrimi-
nating metabolites between NC and iMN patients could be due
to a low number of samples in each group limiting the
statistical strength of the analysis. In addition, the samples
were not matched regarding to the conventional confounding
factors (age, gender, ethnicity, infection screening and urine
collection date). However, it is less of an issue here as the study
aims to identify disruption of the PI on the urine metabotype
(which is largely visible in the NMR and MS spectra) in the
context of a kidney disease and not to evaluate the specific
metabolic signature of the disease itself which is the subject of
future studies.
A decision-making process for the metabolic analysis of
urine samples both with and without a PI addition by
1H NMR spectroscopy, HILIC UPLC-MS and RP UPLC-MS is
proposed in Fig. 4. This includes the following procedures:
– Preparation of quality control samples representative of
each group of interest with the presence or absence of PI for
analysis with the sample set.
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– Measurement of urinary protein levels to evaluate
whether PI addition affects the protein concentrations in the
samples.
– Appropriate data processing (alignment and median fold
change normalisation) and PI peak removal in the 1H NMR
spectra.
– If PI significantly impacts the endogenous metabolites in
the samples, alternative statistical procedures which take into
account confounding factors can be applied to correct for the
presence of PI.36
These procedures can help limit the identification of false
positive and negative markers in urine samples containing
Fig. 4 Flow chart of a proposed decision-making process for metabolic profiling of urine samples with presence and absence of a PI.
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preservatives and ultimately improve the biomarker discovery
in renal disease.
Conclusion
This study demonstrated that it is possible to include proteinuric
urine samples containing a PI for 1H NMR spectroscopic and
HILIC UPLC-MS and RP UPLC-MS metabolic profiling. Careful
data processing is required to eliminate the contribution of the
PI on the 1H NMR dataset. In MS datasets, it is important to
estimate the impact of PI on metabolite ionisation to flag
potential false positive markers. We report a generalizable work-
flow for sample analysis where PI is part of the study design. The
utilisation of urine samples for multi-omics analysis may prove
useful in the identification of new biomarkers for renal diseases
and could allow the development of an individualized treatment
strategy.
Experimental section
Urine collection and storage
This work forms of part of the Eurenomics EC-funded project. Full
ethical approval was obtained by all the clinical collaborators
within the Eurenomics project. All subjects also gave their
informed consent. Once received, and prior to analysis, the
samples were further anonymised by assigning a randomised
study number. The samples were used only for study-specific
objective as agreed with the sample holders prior to commencing
the investigation. Urine samples from normal controls (NC) (n = 4)
and patients with a NS due to biopsy-proven idiopathic mem-
branous nephropathy (iMN) (n = 6) were collected under human
participant research protocols approved by the Institutional
Review Boards of Radboud University Medical Center, The
Netherlands. NS was defined as proteinuria 43 g/24 h and a
serum albumino3.0 g dL1. Urine samples were centrifuged at
3000g for 10 min at 4 1C. The supernatant was divided into two
15 ml aliquots. A protease inhibitor (Complete Mini, Roche,
Indianapolis, IN, USA) was added to one 15 ml aliquot of each
sample. The samples were stored for a year in 2 ml aliquots at
80 1C until further use. Protein content was measured in each
sample by optical density at an absorbance of 600 nm (see
Supplementary material and methods, ESI†). Proteins in the
samples were also precipitated to remove the contribution of
protein peaks in the 1H NMR spectra. To perform the protein
precipitation, the samples were stored at 20 1C overnight with
cold deuterated methanol. The supernatants were collected,
dried down, and stored in 80 1C. Dried protein pellets were
also re-suspended with water prior to protein measurement
(see Supplementary material and methods, ESI†) and 1H NMR
spectroscopic analysis.
1H NMR spectroscopic analysis
Samples were thawed at room temperature and prepared
according to a published protocol.37 Samples that underwent
a protein precipitation were re-suspended with water prior to
sample preparation (see Supplementary material and methods,
ESI†). For each sample, a volume of 350 ml was combined with
350 ml of phosphate buffer (1.5 M KH2HPO4, pH = 7.4, 100%
D2O, 1.9 mM sodium azide and 5 mM trimethylsilyl[
2H4]
propionic acid sodium salt (TSP)). The samples were then
centrifuged for 5 min at 13 000g at 4 1C and 600 ml of the
supernatant was transferred into 5 mm outer diameter NMR
tubes for analysis as published by Dona et al.37 1H NMR spectra
were acquired at a temperature of 300 K, using a standard pulse
sequence with water suppression (noesypr1d, (RD)–901–t1–901–
tm–901–acquisition) at 600.13 MHz, a relaxation delay (RD) of
4 s, a mixing time (tm) of 10 ms, a 901 pulse set at 16.3 ms, and
32 free induction decays (FIDs) using 64 K data-points. The
FIDs were multiplied by an exponential factor to give a line
broadening of 1 Hz and Fourier transformed to obtain the
usual frequency spectrum (TOPSPIN 3.2 software, Bruker
Biospin, Rheinstetten, Germany). The spectra were automati-
cally phased, baseline corrected and calibrated using the TSP
signal at d 0 using a standard Bruker routine, then imported
into MATLAB (version R2014a, the Math works, Natick MA,
USA) and digitised to 32 K data-points. The water peak reso-
nance (d 4.7–5.05) was removed from each spectrum. The
spectra were then aligned using an algorithm published by
Veselkov et al.24 and the chemical shifts from any PI contami-
nants peaks were also excluded from each spectrum. The
1H NMR spectra were normalised with the median fold change
(MFC) or the total area normalisation method38 prior to
statistical analysis (further details on normalisation methods
are given in ESI†).
Mass spectrometry analysis
LC-MS grade solvents were used throughout. A volume of 300 ml
of urine was combined with 900 ml isopropanol (IPA). The
sample:IPA mix was incubated for 2 hours at 20 1C, centri-
fuged at 2700g for 20 min and the supernatant aliquoted.
Quality control (QC) samples were prepared by pooling 100 ml
of each sample. The samples were randomised and maintained
at 4 1C until prior to analysis. Separation of metabolites was
performed using a Waters Acquity Ultra Performance LC system
(Waters, Milford, MA, USA). Each sample was analysed using
RP and HILIC UPLC methods as described in the literature.8,39
The acquisition of ESI-MS data was performed on a Xevo G2
Q-TOF mass spectrometer (Waters, Milford, MA, USA) in positive
and negative ESI modes. The two ionisation modes complement
each other, as metabolites may preferentially ionise in either of
the two modes according to their functional groups- which carry
the charge of the molecule.
Capillary and cone voltages were set at 1.5 kV and 30 V respec-
tively. The desolvation gas was set to 1000 L h1 at a temperature of
600 1C; the cone gas was set to 50 L h1 and the source temperature
was set to 120 1C. For mass accuracy a lockspray interface was
used with a leucine enkephalin (556.27741/554.2615 amu)
solution at a concentration of 2000 ng ml1, at a flow rate
of 15 ml min1 as the lock mass. The raw spectrometric data
were processed using XCMS (version 1.50.0) in R (3.1.2, R
Foundation for Statistical Computing, Vienna, Austria),
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using the centwave peak picking method to detect chromato-
graphic peaks.40
Data analysis
1H NMR and UPLC-MS pre-processed data were analysed using
a multivariate approach in SIMCA (SIMCA-P13 UMETRICS,
Umea, Sweden). PCA was performed using the full resolution
NMR (32 K data points) and MS data to assess sample clustering
behaviour and intra-group variation. OPLS-DA was employed to
maximise the metabolic differences between groups corres-
ponding to NC, NC + PI, iMN and iMN + PI.23 The OPLS-DA
model with a CV-ANOVA p-value o 0.05 was considered as
predictive. Wilcoxon–Mann–Whitney (WMW) tests, adjusted
using the Benjamini–Hochberg False Discovery Rate (pFDR),
were also calculated for each feature. However, considering the
low number of samples, the important features for group
discrimination were identified if they had WMW p-values o
0.05 regardless of pFDR values.
Metabolite identification
Metabolite assignments in NMR data were performed by
matching the chemical shifts and J-coupling information with
NMR spectral databases41 and literature. STOCSY (Statistical
Total Correlation SpectroscopY)19 as well as 2-D 1H–13C and
1H–1H NMR experiments, were employed to help the identifi-
cation of unknown metabolites.
The metabolite identification in MS data was achieved by
comparing the molecular weight and MS–MS fragmentation
patterns of the features of interest with available literature and
online databases such as METLIN,42 and the Human Metabolome
Database (HMDB).41
Abbreviations
NS Nephrotic syndrome
PI Protease inhibitor
NC Normal control
iMN (Idiopathic) membranous nephropathy
UPLC-MS Ultra-performance liquid chromatography-
mass spectrometry
NMR Nuclear magnetic resonance
RP Reverse phase
ESI Electrospray ionisation
MVA Multivariate analysis
iFSGS (Idiopathic) focal segmental
glomerulosclerosis
MCD Minimal change disease
CKD Chronic kidney disease
TSP Trimethylsilyl[2H4]propionic acid
FID Free induction decay
RD Relaxation delay
MFC Median fold change
QC Quality control
PCA Principal component analysis
OPLS Orthogonal partial least squares
OPLS-DA OPLS-discriminant analysis
AEBSF 4-(2-Aminoethyl)benzenesulfonyl fluoride
hydrochloride
STOCSY Statistical total correlation spectroscopy
J-Res J-Resolved
STORM Subset optimization by reference matching.
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